Enlicitide

Merck & Co. · MK-0616

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
6 active
34 in total · 8 in the EU
Targets
 

What this is

How it works
PCSK9 inhibitor (oral macrocyclic peptide)
Tested for
Hypercholesterolemia (2 trials), Hyperlipidemia, Arteriosclerosis, Hypercholesterolaemia, Heterozygous Familial Hypercholesterolemia (HeFH), Lipoprotein(a)
Main trialPhase 3
“Researchers are looking for new ways to treat high cholesterol. Cholesterol is a type of fat in the blood. Enlicitide (also known as enlicitide decanoate or MK-0616), the study medicine, is in a class of medicines designed to lower low-density lipoprotein cholesterol (LDL-C). LDL-C is sometimes called "bad cholesterol." The goal of this study is to learn if enlicitide works better than placebo to lower the amount of LDL-C in a person's blood. Researchers also want to learn about the safety of enlicitide and if people tolerate it.”In the company’s words, NCT07821944 on ClinicalTrials.gov
Other names
MK-0616 · Lipfendra

Other drugs for Hypercholesterolemia

All 21 drugs for Hypercholesterolemia

Coming up6

Changes1

Last 90 days

Trials34

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 26 Nov 2027 A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)
Phase 3Active, not recruiting 13 Oct 2028 Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
Phase 3Active, not recruiting 29 Nov 2029 Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
Phase 2/3Recruiting 4 Dec 2033 A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Phase 2Recruiting 12 Oct 2027 A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Phase 1Active, not recruiting 14 Dec 2026 A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)
Phase 3Completed 14 Feb 2025 A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
Phase 3Completed 7 Apr 2025 A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
Phase 3Completed 28 Jul 2025 A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
Phase 3Completed 3 Aug 2026 A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Phase 2Completed 28 Nov 2022 A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
Phase 1Completed 29 Dec 2022 A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)
Phase 1Completed 3 May 2023 A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)
Phase 1Completed 8 May 2023 A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)
Phase 1Completed 2 Aug 2023 A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)
Phase 1Completed 26 Dec 2023 The Effect of Food and Water Volume in Healthy Adult Participants Administered Enlicitide Decanoate (MK-0616) (MK-0616-022)
Phase 1Completed 29 Dec 2023 A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)
Phase 1Completed 2 Jan 2024 A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)
Phase 1Completed 19 Jan 2024 Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)
Phase 1Completed 1 May 2024 A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)
Phase 1Completed 24 May 2024 A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
Phase 1Completed 4 Jun 2024 A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)
Phase 1Completed 21 Jun 2024 A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)
Phase 1Completed 19 Aug 2024 A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)
Phase 1Completed 1 Nov 2024 A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
Phase 1Completed 13 Jan 2025 A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)
Phase 1Completed 27 Jan 2025 A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034)
Phase 1Completed 1 May 2025 A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)
Phase 1Completed 16 May 2025 A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)
Phase 1Completed 25 Jun 2025 A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
Phase 1Completed 13 Aug 2025 A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)
Phase 1Completed 18 May 2026 A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)
Phase 1Completed 5 Sep 2026 A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)
Phase 1Completed 14 Oct 2026 A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Enlicitide

Following is part of Solo: you see every change to Enlicitide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in